Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD

About

This is a long-term extension study that allows for open-label dosing or re-dosing for participants who did not respond in the first two Cybin for MDD studies, or relapsed during the extension study

Enrollment Status & Eligibility

Participants are invited to participate in this trial following the completion of the first two Cybin for MDD studies. We are not recruiting participants outside of the initial studies—this is an extension for existing participants.

Location

This study will be conducted at InnerMost, in NoMad, Manhattan, New York City.

Cost

All study-related care and medication are provided at no cost, and participants are compensated for time and travel.

Safety & Support

Every dosing session takes place in a supportive environment with trained, experienced professionals. Safety is a priority—participants are carefully monitored throughout, and integration support is provided after each experience.

For more information about this study, click here.